<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115073</url>
  </required_header>
  <id_info>
    <org_study_id>ProF-001_Phase IIa</org_study_id>
    <nct_id>NCT03115073</nct_id>
  </id_info>
  <brief_title>ProF-001_Phase IIa</brief_title>
  <official_title>A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProFem GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProFem GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, prospective, active-controlled, double-blind,
      dose-escalation study comparing dose response of clinical efficacy, safety, local
      tolerability of three different doses of ProF-001/Candiplus® (Candiplus® 0.2%, Candiplus®
      with 0.3%, Candiplus® with 0.4%) to 1% clotrimazole vaginal cream.

      Patients with acute episode of vulvovaginal candidiasis (VVC) will be randomized to receive a
      daily dose of either 5 ml (intravaginal) of Candiplus® at three different doses for the first
      3 days and 2.5 ml for the remaining 3 days or 5 ml (intravaginal) application of 1%
      clotrimazole cream over the first 3 days and 2.5 ml for the remaining 3 days according to the
      following scheme (with each application 2 cm of cream will be applied to the vulvar region):

      Cohort 1: Candiplus® 0.2% versus clotrimazole mono Cohort 2: Candiplus® 0.3% versus
      clotrimazole mono Cohort 3: Candiplus® 0.4% versus clotrimazole mono Randomization into the
      cohorts will occur consecutively from the lowest dose to the highest dose, i.e. patients will
      be randomized first in cohort 1 and finally in cohort 3.

      The proposed study is - after a pilot study to assess critical pharmacokinetic data - the
      second study within a clinical trial program with the objective to develop a new combination
      therapy for the treatment of vulvovaginal candidiasis.

      The new combination consists of two registered drug substances.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2017</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined outcome measure of: Symptom relief within the first 60 minutes (after application of investigational product or active control) and clinical cure at day 7 (± 3 days).</measure>
    <time_frame>within 60 minutes after application and at day 7 (± 3 days) after drug application</time_frame>
    <description>As the primary outcome symptom relief within the first 60 minutes will be documented. A reduction of the subjective symptom score ≥ 2 is expected. Furthermore clinical cure at day 7 will be documented. Clinical cure is defined as absence of signs and symptoms of VVC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with local adverse events and serious adverse events (SAEs) with causal relationship to study medication</measure>
    <time_frame>overall study period (max. 65 days)</time_frame>
    <description>All local adverse events and serious adverse events with causal relationship to study medication (drug reaction) will be documented in a descriptive manner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom relief within the first 60 minutes (after application of investigational product or active control, reduction of the subjective symptom score ≥ 2)</measure>
    <time_frame>within 60 minutes after drug application</time_frame>
    <description>Symptom relief within the first 60 minutes will be documented. A reduction of the subjective symptom score ≥ 2 is expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure (absence of signs and symptoms of VVC) at the TOC visit (=day 7/ accepted time window ±3days)</measure>
    <time_frame>day 7 ±3 days after drug application</time_frame>
    <description>Clinical cure at day 7 will be documented. Clinical cure is defined as absence of signs and symptoms of VVC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological outcome: Vaginal swab culture negative for growth of Candida albicans and/or Candida species at the TOC visit (day 7 / ±3days)</measure>
    <time_frame>day 7 ±3 days after drug application</time_frame>
    <description>A vaginal swab culture will be taken on day 7 / ±3days. The test result is expected to be negative for growth of Candida albicans and/or Candida species.visit (day 7 / ±3days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder outcome: absence of signs and symptoms plus vaginal swab culture negative for growth of Candida albicans and/or Candida species at the TOC visit (day 7 / ±3days)</measure>
    <time_frame>day 7 ±3 days after drug application</time_frame>
    <description>Presence or absence of signs and symptoms will be documented. Vaginal swab culture is expected to be negative for growth of Candida albicans and/or Candida species at the TOC visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement of symptoms after first intervention</measure>
    <time_frame>overall study period (max. 65 days)</time_frame>
    <description>The time to improvement of symptoms after the first intervention will be documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to termination of clinical symptoms</measure>
    <time_frame>overall study period (max. 65 days)</time_frame>
    <description>The time to termination of clinical symptoms will be documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical relapse of VVC during follow-up period</measure>
    <time_frame>follow-up period (from day 8 to day 60)</time_frame>
    <description>Every clinical relapse of VVC during the follow-up period will be documented.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Vulvovaginal Candidiasis (VVC)</condition>
  <arm_group>
    <arm_group_label>0,2% Candiplus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candiplus® 0.2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0,3% Candiplus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candiplus® 0.3%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0,4% Candiplus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candiplus® 0.4%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clotri mono</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clotrimazole mono</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candiplus</intervention_name>
    <description>Administration of Candiplus</description>
    <arm_group_label>0,2% Candiplus</arm_group_label>
    <arm_group_label>0,3% Candiplus</arm_group_label>
    <arm_group_label>0,4% Candiplus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole</intervention_name>
    <description>Administration of Clotrimazole</description>
    <arm_group_label>Clotri mono</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal female patients ≥ 18 years old

          -  Patients suffering from an acute episode of vulvovaginal candidiasis, characterized
             by:

               -  Positive vaginal smear (native, KOH) for budding yeasts and/or fungal (pseudo-)
                  hyphae, normal or intermediate flora (G I and G II)

               -  Positive clinical symptoms (itching, burning, irritation, edema, erythema,
                  excoriations), with a subjective symptom score of at least 3 (0=absent, 1=mild,
                  2=moderate, and 3=severe), with score being at least moderate for at least 1
                  subjective symptom and itching being present, and a total sign and symptom score
                  of at least 4

          -  Readiness for sexual abstinence from start of treatment until test of cure (TOC) -
             visit

          -  Sufficient knowledge of German language to understand trial instructions and rating
             scales, and ability to comply with treatment

          -  Written informed consent prior to enrolment

        Exclusion Criteria:

          -  Known hypersensitivity to any ingredient of the investigational medicinal product

          -  Pregnancy or breast feeding at time of screening

          -  Menstrual bleeding (spotting is not an exclusion criterion) during the first three
             days of treatment

          -  Acute cystitis

          -  Patients with clinical signs of other infectious causes of vulvovaginitis: bacterial
             vaginosis (GIII), trichomonas vaginalis, herpes simplex genitalis

          -  Treatment with antimycotics (systemic or vaginal) within 7 days of randomization

          -  Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs)

          -  Patients with other clinical gynecological abnormalities, such as infections of the
             upper urogenital tract (pelvic inflammatory disease, adnexitis)

          -  Subjects with another vaginal or vulvar condition that would confound the
             interpretation of clinical response (e.g. Lichen sclerosus, neuropathic pain)

          -  Subjects who will be under treatment or surgery for gynecological pathologies during
             the study period, i.e, cervical intraepithelial neoplasia, cervical carcinoma, other
             neoplasms

          -  Known alcohol, drug or medication abuse

          -  Any clinically relevant concomitant condition that could compromise the objectives of
             this study and/ or the patient's compliance (eg. known immune deficiency syndrome with
             clinical relevance at time of screening)

          -  Participation in another interventional clinical trial within the last 30 days

          -  Employee at the study site, spouse/partner or relative of any study staff (e.g.,
             investigator, sub-investigators, or study nurse) or relationship to the sponsor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Kiss, Ao.Univ.Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion Noe-Letschnig, DI DDr.</last_name>
    <phone>+43 676 7203070</phone>
    <email>marion.noe@profem.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bezirkskrankenhaus Schwaz</name>
      <address>
        <city>Schwaz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://archives.who.int/eml/expcom/expcom14/clotrimazole/clotrimazole_ECP_review_16feb05.pdf</url>
    <description>Lisa A. Bero, February 15, 2005, Expert Committee on Selection and Use of Essential Medicines, Review of Application of Clotrimazole for topical or intravaginal use in vulvovaginal candidiasis.</description>
  </link>
  <link>
    <url>https://www.medicines.org.uk/emc/medicine/6136</url>
    <description>T Becker, Walter Siegenthaler MMV Award 2005, Geriatrie Praxis 2005, 7, 2-3.Canesten Fungal Infection 1% cream, UK SmPC, 2015</description>
  </link>
  <link>
    <url>http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM509411.pdf</url>
    <description>FDA draft Guidance for Industry Vulvovaginal Candidiasis —Developing Drugs for Treatment, 2016.</description>
  </link>
  <link>
    <url>https://pdfs.semanticscholar.org/370b/92bc4f61fedfa64e1b50e7a10c7a6dde0a19.pdf</url>
    <description>Newcombe, R.G. &quot;Interval estimation for the difference between independent proportions: comparison of eleven methods&quot; Statistics in Medicine 17(1988) pp. 873-890</description>
  </link>
  <link>
    <url>http://mic.microbiologyresearch.org/content/journal/micro/10.1099/13500872-140-11-2971</url>
    <description>Santoni G, Gismondi A, Liu JH, et al. Candida albicans expresses a fibronectin receptor antigenically related to a5b1 integrin. Microbiology. 1994 Nov;140 ( Pt 11):2971-9.</description>
  </link>
  <link>
    <url>https://www.medicines.org.uk/emc/print-document?documentId=21038</url>
    <description>Voltarol 1.16% Emulgel, UK SmPC 2016</description>
  </link>
  <link>
    <url>https://www.medicines.org.uk/emc/medicine/1344</url>
    <description>Voltarol Suppositories 12.5 mg, 25 mg, 50 mg, 100 mg, UK SmPC 2013</description>
  </link>
  <reference>
    <citation>Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010 Apr;23(2):253-73. doi: 10.1128/CMR.00076-09. Review.</citation>
    <PMID>20375352</PMID>
  </reference>
  <reference>
    <citation>Alem MA, Douglas LJ. Prostaglandin production during growth of Candida albicans biofilms. J Med Microbiol. 2005 Nov;54(Pt 11):1001-5.</citation>
    <PMID>16192429</PMID>
  </reference>
  <reference>
    <citation>Donders G, Bellen G, Byttebier G, Verguts L, Hinoul P, Walckiers R, Stalpaert M, Vereecken A, Van Eldere J. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol. 2008 Dec;199(6):613.e1-9. doi: 10.1016/j.ajog.2008.06.029. Epub 2008 Oct 30.</citation>
    <PMID>18976735</PMID>
  </reference>
  <reference>
    <citation>Dovnik A, Golle A, Novak D, Arko D, Takač I. Treatment of vulvovaginal candidiasis: a review of the literature. Acta Dermatovenerol Alp Pannonica Adriat. 2015;24(1):5-7. Review.</citation>
    <PMID>25770305</PMID>
  </reference>
  <reference>
    <citation>Cannom RR, French SW, Johnston D, Edwards JE Jr, Filler SG. Candida albicans stimulates local expression of leukocyte adhesion molecules and cytokines in vivo. J Infect Dis. 2002 Aug 1;186(3):389-96. Epub 2002 Jul 11.</citation>
    <PMID>12134235</PMID>
  </reference>
  <reference>
    <citation>Filler SG, Pfunder AS, Spellberg BJ, Spellberg JP, Edwards JE Jr. Candida albicans stimulates cytokine production and leukocyte adhesion molecule expression by endothelial cells. Infect Immun. 1996 Jul;64(7):2609-17.</citation>
    <PMID>8698486</PMID>
  </reference>
  <reference>
    <citation>Gale CA, Bendel CM, McClellan M, Hauser M, Becker JM, Berman J, Hostetter MK. Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INT1. Science. 1998 Feb 27;279(5355):1355-8.</citation>
    <PMID>9478896</PMID>
  </reference>
  <reference>
    <citation>Haynes K. Virulence in Candida species. Trends Microbiol. 2001 Dec;9(12):591-6. Review.</citation>
    <PMID>11728872</PMID>
  </reference>
  <reference>
    <citation>King RD, Lee JC, Morris AL. Adherence of Candida albicans and other Candida species to mucosal epithelial cells. Infect Immun. 1980 Feb;27(2):667-74.</citation>
    <PMID>6991423</PMID>
  </reference>
  <reference>
    <citation>Klotz SA. Fungal adherence to the vascular compartment: a critical step in the pathogenesis of disseminated candidiasis. Clin Infect Dis. 1992 Jan;14(1):340-7. Review.</citation>
    <PMID>1571448</PMID>
  </reference>
  <reference>
    <citation>Kolachala VL, Bajaj R, Wang L, Yan Y, Ritzenthaler JD, Gewirtz AT, Roman J, Merlin D, Sitaraman SV. Epithelial-derived fibronectin expression, signaling, and function in intestinal inflammation. J Biol Chem. 2007 Nov 9;282(45):32965-73. Epub 2007 Sep 13.</citation>
    <PMID>17855340</PMID>
  </reference>
  <reference>
    <citation>Mathé L, Van Dijck P. Recent insights into Candida albicans biofilm resistance mechanisms. Curr Genet. 2013 Nov;59(4):251-64. doi: 10.1007/s00294-013-0400-3. Epub 2013 Aug 25. Review.</citation>
    <PMID>23974350</PMID>
  </reference>
  <reference>
    <citation>Mendling W, Krauss C, Fladung B. A clinical multicenter study comparing efficacy and tolerability of topical combination therapy with clotrimazole (Canesten, two formats) with oral single dose fluconazole (Diflucan) in vulvovaginal mycoses. Mycoses. 2004 Apr;47(3-4):136-42.</citation>
    <PMID>15078430</PMID>
  </reference>
  <reference>
    <citation>Muzny CA, Schwebke JR. Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections. Clin Infect Dis. 2015 Aug 15;61(4):601-6. doi: 10.1093/cid/civ353. Epub 2015 May 1. Review.</citation>
    <PMID>25935553</PMID>
  </reference>
  <reference>
    <citation>Naglik J, Albrecht A, Bader O, Hube B. Candida albicans proteinases and host/pathogen interactions. Cell Microbiol. 2004 Oct;6(10):915-26. Review.</citation>
    <PMID>15339267</PMID>
  </reference>
  <reference>
    <citation>Noverr MC, Phare SM, Toews GB, Coffey MJ, Huffnagle GB. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect Immun. 2001 May;69(5):2957-63.</citation>
    <PMID>11292712</PMID>
  </reference>
  <reference>
    <citation>Noverr MC, Huffnagle GB. Regulation of Candida albicans morphogenesis by fatty acid metabolites. Infect Immun. 2004 Nov;72(11):6206-10.</citation>
    <PMID>15501745</PMID>
  </reference>
  <reference>
    <citation>Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991 Feb;29(2):297-301.</citation>
    <PMID>1706728</PMID>
  </reference>
  <reference>
    <citation>Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009 May;2(3):155-63. doi: 10.1161/CIRCOUTCOMES.108.805689. Epub 2009 May 5.</citation>
    <PMID>20031832</PMID>
  </reference>
  <reference>
    <citation>Schaller M, Mailhammer R, Korting HC. Cytokine expression induced by Candida albicans in a model of cutaneous candidosis based on reconstituted human epidermis. J Med Microbiol. 2002 Aug;51(8):672-6.</citation>
    <PMID>12171298</PMID>
  </reference>
  <reference>
    <citation>Schaller M, Mailhammer R, Grassl G, Sander CA, Hube B, Korting HC. Infection of human oral epithelia with Candida species induces cytokine expression correlated to the degree of virulence. J Invest Dermatol. 2002 Apr;118(4):652-7.</citation>
    <PMID>11918712</PMID>
  </reference>
  <reference>
    <citation>Sobel JD, Schmitt C, Stein G, Mummaw N, Christensen S, Meriwether C. Initial management of recurrent vulvovaginal candidiasis with oral ketoconazole and topical clotrimazole. J Reprod Med. 1994 Jul;39(7):517-20.</citation>
    <PMID>7966041</PMID>
  </reference>
  <reference>
    <citation>Sobel JD, Kapernick PS, Zervos M, Reed BD, Hooton T, Soper D, Nyirjesy P, Heine MW, Willems J, Panzer H, Wittes H. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol. 2001 Aug;185(2):363-9.</citation>
    <PMID>11518893</PMID>
  </reference>
  <reference>
    <citation>Théraud M, Bédouin Y, Guiguen C, Gangneux JP. Efficacy of antiseptics and disinfectants on clinical and environmental yeast isolates in planktonic and biofilm conditions. J Med Microbiol. 2004 Oct;53(Pt 10):1013-8.</citation>
    <PMID>15358824</PMID>
  </reference>
  <reference>
    <citation>Thompson DS, Carlisle PL, Kadosh D. Coevolution of morphology and virulence in Candida species. Eukaryot Cell. 2011 Sep;10(9):1173-82. doi: 10.1128/EC.05085-11. Epub 2011 Jul 15. Review.</citation>
    <PMID>21764907</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vulvovaginal candidiasis</keyword>
  <keyword>Candiplus</keyword>
  <keyword>Clotrimazole</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Clinical efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

